increas price base earn updat
preliminari data highlight cbmg abstract
discuss note highlight key takeaway
recent releas abstract found present first-in-
human data product candid autolog anti-bcma car-t
decemb believ compani attract partnership target
 -base compani look china-bas collabor manufactur
expertis clinic asset
expect posit initi data present
recent releas abstract present initi data three patient
treat first dose level phase iit dose escal studi c-
autolog anti-bcma car-t treatment patient
relapsed/refractori multipl myeloma data cutoff date patient
juli expect see follow-up data confer
confirm least patient treat trial thu far
mean could also see initi clinic data confer
patient treat second dose level term compani
manufactur capabl could see increment data around vein-to-
vein time and/or cost per treatment believ compar favor
manufactur capabl make ideal china-bas partner
squar feet manufactur space across four facil
china squar feet intern cgmp-compliant
importantli compani also develop key manufactur partnership
ge rate thermo fisher buy pt
analyst sung ji nam suspect compani current cost per dose
least compani space addit believ
manufactur time car-t cell therapi could low eight day
current standard day opinion
compani licens collabor agreement novarti nv rate
compani gain right exclus manufactur
kymriah china serv valid manufactur capabl see
opportun addit partnership futur given increas effort
 -base compani expand china latest exampl
rate pay billion stake beigen bgne
rate astrazeneca azn-lon rate partner state-own
invest bank cicc billion fund invest local biotech startup
effort driven on-going reform nmpa
detail initi
valuat increas price target base assumpt
receiv approv nmpa china versu
prior estim approv also increas probabl
approv product candid serv
valid cbmg capabl increas estim valu
compani platform current nearli million cash given
compani burn million per quarter expect dilut occur
addit detail found next page summari
valuat tabl shown page
idc btig estim compani document
million except per share amount
develop cgmp grade cell therapi manufactur capabl nearli decad
squar feet manufactur space across four facil china compani manufactur capabl
valid collabor novarti compani gain right exclus
manufactur kymriah china addit develop pipelin wholli own immuno-oncolog
product leverag number therapeut modal includ number product candid either clinic
expect clinic within next month
initi registr trial kymriah china expect end
approv nmpa expect end
file accept ind applic china initi safeti
efficaci data phase iit china patient r/r mm
expect decemb
initi safeti efficaci data on-going phase iit china
patient r/r dlbcl r/r sll/cll expect
initi clinic trial china compani bi-
specif car-t product candid expect
initi clinic trial dose first patient china either tcr-t
cell product candid til product candid expect late earli
base case model assum kymriah receiv approv china r/r
r/r nhl assum entitl royalti payment equal
total treatment revenu mark-up manufactur
assum receiv approv china chanc
assum receiv approv china chanc
kymriah assum probabl drug receiv
approv china upsid scenario compar base case
assum chanc receiv approv upsid
scenario compar base
similarli assum chanc receiv approv
upsid scenario compar base case
base assumpt upsid scenario arriv price target
downsid scenario remov valu compani platform
estim valu wholli own product candid current
assum kymriah chanc receiv approv china
downsid scenario compar base case
base assumpt downsid scenario calcul price
clinical-stag biopharmaceut
compani broad pipelin
therapi tcr-t cell therapi
primari target market china
own gmp facilti
develop signific
licens collabor
agreement novarti
manufactur suppli fda-
product kymriah china
candid anti-
bcma car-t cell therapi
treatment multipl myeloma
probability-weight npv million probability-weight npv per shareprobability-weight npv million probability-weight npv per shareprobability-weight npv million probability-weight npv per sharekymriahal dlbcl- less upsid casetot npv pipelinenpv platformtot enterpris valuetot market capitalizationproduct candidatetarget indic downsid casebas case
factset btig estim
inc incom statementfisc year end decemb thousand except per share sale oper expens gener sell research impair long-term total oper oper incom interest incom expens incom expens net incom loss incom tax credit net incom weighted-averag share net incom loss per growth metric year-over-year collabor expens gener oper incom loss nmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incom loss nmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmgrowth metric quarter-over-quart collabor expens gener oper incom loss nananananmnmnmnmnanmnmnmnmnanananet incom loss nananananmnmnmnmnanmnmnmnmnananaamanda murphi
btig cover compani mention report
appendix analyst certif import disclosur
